Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses.
COVID-19
Comorbidities
Diabetes mellitus
Rheumatic diseases
Rheumatoid arthritis
Systemic lupus erythematosus
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
28
07
2022
accepted:
01
09
2022
revised:
31
08
2022
pubmed:
9
9
2022
medline:
16
11
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
Outcomes of COrona VIrus Disease-19 (COVID-19) in patients with rheumatic diseases (RDs) reported in various studies are heterogenous owing to the influence of age and comorbidities which have a significant bearing on the infection risk, severity, morbidity, and mortality. Diabetes mellitus (DM) and RDs are closely linked with underlying pathobiology and treatment of RDs affecting the risk for DM as well as the glycemic control. Hence, we undertook this narrative review to study the influence of DM on outcomes of COVID-19 in patients with RDs. Additionally, aspects of patient attitudes and immune response to COVID-19 vaccination were also studied. The databases of MEDLINE/PubMed, Scopus, and Directory of Open Access Journals (DOAJ) were searched for relevant articles. Studies from mixed cohorts revealed insufficient data to comment on the influence of DM on the risk of infection, while most studies showed twice the odds for hospitalization and mortality with DM. Specific cohorts of rheumatoid arthritis and systemic lupus erythematosus revealed a similar association. Poor health was noted in patients with spondyloarthritis and DM during the pandemic. The presence of DM did not affect patient attitudes towards vaccination and did not predispose to additional vaccine-related adverse effects. Immune response to inactivated vaccines was reduced but mRNA vaccines were maintained in patients with DM. Detailed assessment of DM with its duration, end-organ damage, and glycemic control along with a focused association of DM with various aspects of COVID-19 like risk, hospitalization, severity, mortality, post-COVID sequelae, immune response to infection, and vaccination are needed in the future. Key Points • Diabetes mellitus is associated with the severity of infection, COVID-19-related hospitalization, and mortality in rheumatic diseases across most studies but studies analyzing its specific role are lacking. • Poor outcomes of COVID-19 in RA and poor health in spondyloarthritis are strongly associated with diabetes mellitus. • Diabetes mellitus may negatively influence the humoral response to inactivated vaccines but does not seem to affect the immune responses to mRNA vaccines. • Diabetes mellitus does not influence the attitude towards vaccination or deviation from the prescribed medications during the pandemic.
Identifiants
pubmed: 36076125
doi: 10.1007/s10067-022-06365-y
pii: 10.1007/s10067-022-06365-y
pmc: PMC9458477
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3897-3913Informations de copyright
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
J Korean Med Sci. 2020 Jun 29;35(25):e237
pubmed: 32597048
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann Palliat Med. 2021 Mar;10(3):2723-2735
pubmed: 33549005
Ann Rheum Dis. 2021 Oct;80(10):1322-1329
pubmed: 34362747
RMD Open. 2021 Dec;7(3):
pubmed: 34887346
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Ann Rheum Dis. 2020 Sep;79(9):1170-1173
pubmed: 32532753
Arthritis Rheumatol. 2021 Dec;73(12):2179-2188
pubmed: 33955209
Clin Rheumatol. 2021 Nov;40(11):4527-4531
pubmed: 34189674
J Rheumatol. 2021 Mar;48(3):454-462
pubmed: 33132221
RMD Open. 2022 Apr;8(1):
pubmed: 35383121
Curr Opin Rheumatol. 2009 Jan;21(1):50-4
pubmed: 19077719
Ann Rheum Dis. 2021 Feb;80(2):e16
pubmed: 32434823
Arch Rheumatol. 2021 Jun 24;36(4):473-481
pubmed: 35382368
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Arthritis Rheumatol. 2020 Dec;72(12):1971-1980
pubmed: 32715660
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
JAMA Netw Open. 2021 Oct 1;4(10):e2129639
pubmed: 34661663
Clin Rheumatol. 2020 Sep;39(9):2789-2796
pubmed: 32720259
Arthritis Rheum. 2003 Nov;48(11):3159-67
pubmed: 14613278
J Multidiscip Healthc. 2021 Apr 12;14:809-820
pubmed: 33880030
Clin Rheumatol. 2021 Jul;40(7):2633-2642
pubmed: 33420870
Immun Inflamm Dis. 2022 Mar;10(3):e589
pubmed: 35099852
Nat Rev Endocrinol. 2021 Jan;17(1):11-30
pubmed: 33188364
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI59-SI67
pubmed: 33369663
J Autoimmun. 2021 Feb;117:102580
pubmed: 33338707
Rheumatol Int. 2022 Jan;42(1):31-39
pubmed: 34739573
Rheumatol Int. 2020 Oct;40(10):1593-1598
pubmed: 32794113
Ann Rheum Dis. 2022 Jul;81(7):1028-1035
pubmed: 35418481
Ther Adv Musculoskelet Dis. 2022 Jan 19;14:1759720X211066685
pubmed: 35069810
J Korean Med Sci. 2022 Jun 06;37(22):e176
pubmed: 35668686
Ann Rheum Dis. 2022 Apr;81(4):569-574
pubmed: 34893471
Curr Rheumatol Rev. 2022;18(3):234-242
pubmed: 35418287
Clin Rheumatol. 2021 Nov;40(11):4665-4670
pubmed: 34155573
Rheumatol Int. 2021 Jun;41(6):1097-1103
pubmed: 33856543
J Rheumatol. 2006 Jan;33(1):50-6
pubmed: 16395749
Ann Intensive Care. 2020 Jul 31;10(1):99
pubmed: 32737627
Clin Exp Rheumatol. 2022 Jan-Feb;40(1):195-196
pubmed: 34369358
Ann Rheum Dis. 2021 Mar;80(3):384-391
pubmed: 33051220
Rheumatol Autoimmun. 2022 Jun;2(2):82-91
pubmed: 35651484
Ann Rheum Dis. 2022 Jul;81(7):970-978
pubmed: 35172961
Lupus. 2001;10(2):81-6
pubmed: 11237130
J Autoimmun. 2021 Dec;125:102743
pubmed: 34757289
Ann Rheum Dis. 2020 Dec;79(12):1544-1549
pubmed: 32796045
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
J Clin Med. 2021 Aug 27;10(17):
pubmed: 34501290
Clin Rheumatol. 2022 Nov;41(11):3537-3542
pubmed: 35760938
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Ann Rheum Dis. 2022 Jun;81(6):868-874
pubmed: 35135831
Rheumatol Int. 2021 Dec;41(12):2167-2175
pubmed: 34580754
N Engl J Med. 2020 Jul 2;383(1):85-88
pubmed: 32348641
Int J Clin Pract. 2022 Jan 31;2022:5931506
pubmed: 35685586
Arthritis Rheumatol. 2016 May;68(5):1089-98
pubmed: 26663814
J Autoimmun. 2021 Dec;125:102730
pubmed: 34649723
Front Endocrinol (Lausanne). 2019 Jul 04;10:451
pubmed: 31333589
Rheumatol Int. 2021 Feb;41(2):243-256
pubmed: 33388969
Cardiovasc Endocrinol Metab. 2021 Feb 19;10(2):125-131
pubmed: 34124603
Rheumatol Int. 2011 Nov;31(11):1409-17
pubmed: 21800117
Front Immunol. 2021 Apr 16;12:651715
pubmed: 33936073
RMD Open. 2021 Jan;7(1):
pubmed: 33510041
Ann Rheum Dis. 2021 Jul;80(7):930-942
pubmed: 33504483
Arthritis Care Res (Hoboken). 2021 Sep;73(9):1322-1331
pubmed: 33787086
Lancet Diabetes Endocrinol. 2022 May;10(5):311-321
pubmed: 35325624
Cureus. 2022 Apr 29;14(4):e24585
pubmed: 35651432
Ann Rheum Dis. 2021 Apr;80(4):527-538
pubmed: 33268442
Ann Rheum Dis. 2020 Nov;79(11):1393-1399
pubmed: 32769150